Stockscreener 앱 받기
131.07
0.45%
0.59
Merck Co Inc 주식(MRK)의 최신 뉴스
Merck & Co. stock holds after recent earnings and pipeline data - AD HOC NEWS
Merck & Co. Launches Early Access Program for Alimatravir - GuruFocus
Merck stock trades steadily as recent Keytruda momentum and solid oncology revenue frame valuation - AD HOC NEWS
Merck & Co., Inc. Revenue Breakdown – VIE:MRK - TradingView
Merck licenses experimental HIV pill to generic makers in 129 countries - Reuters
Merck signs licensing deals with companies including Viatris for new HIV pill - Seeking Alpha
Merck stock steadies as Keytruda drives Q1 2026 revenue growth - AD HOC NEWS
Merck stock holds recent gains as oncology and vaccines drive higher 2025 guidance - AD HOC NEWS
Merck's Once-Monthly HIV Prevention Pill Could Reach 129 Countries if Approved - Stock Titan
2 Top Growth Stocks to Buy Right Now Without Any Hesitation - The Motley Fool
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck stock trades steadily as Keytruda revenue supports earnings - Ad-hoc-news.de
MRK Stock Quote Price and Forecast - CNN
Merck stock trades steadily as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds support after recent earnings and guidance - Ad-hoc-news.de
Return on assets % of Merck & Co., Inc. – BCS:MRK1 - TradingView
Operating margin % of Merck & Co., Inc. – BCS:MRKCL0 - TradingView
Net debt of Merck & Co., Inc. – BCS:MRK1 - TradingView
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRK0 - TradingView
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Commerzbank Aktiengesellschaft FI Decreases Stake in Merck & Co., Inc. $MRK - InsuranceNewsNet
Merck stock trades steadily as Keytruda and vaccine revenue underpin earnings - Ad-hoc-news.de
Merck stock trades steady as oncology and vaccines drive revenue growth - Ad-hoc-news.de
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $2,270,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck stock trades steadily as Keytruda growth underpins guidance - Ad-hoc-news.de
Merck & Co., Inc. (MRK) Stock Analysis: Navigating a 5.13% Upside Potential Amid Robust Growth - DirectorsTalk Interviews
Merck stock trades steady as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds firm as Keytruda drives revenue growth and late stage pipeline advances - ad-hoc-news.de
Merck stock holds steady as Keytruda drives revenue growth and investors watch oncology momentum - ad-hoc-news.de
Is Merck's Recent Restructuring a Confident Pivot or a Defensive Maneuver - Kavout | AI
Merck stock trades steady as Keytruda growth supports earnings outlook - ad-hoc-news.de
Merck stock trades steady as Keytruda growth underpins recent earnings - ad-hoc-news.de
Merck stock trades firm as Keytruda growth supports guidance - ad-hoc-news.de
Merck stock steadies as Keytruda drives double digit growth - ad-hoc-news.de
ETFs Investing in Merck & Co., Inc. Stocks - TradingView
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK) - Seeking Alpha
Merck stock trades near record territory as oncology and vaccines drive revenue growth - ad-hoc-news.de
MRK Stock Climbs As New Drugs And Targets Fuel Bull Case - StocksToTrade
New Cholesterol Pill, Earnings Growth Boost Merck Shares - FXEmpire
Merck stock edges higher as Keytruda drives double digit growth - ad-hoc-news.de
DUPONT CAPITAL MANAGEMENT Corp's Merck & Co Inc(MRK) Holding History - GuruFocus
Earnings preview: What to expect from Merck & Co.'s report - MSN
China’s First Homegrown 9-Valent HPV Vaccine Challenges Merck’s Retreat - Caixin Global
Merck & Co Inc (MRK) Shares Surge 3.2% -- What GF Score of 72 Te - GuruFocus
Merck stock holds gains as Keytruda drives double digit revenue growth - ad-hoc-news.de
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Benzinga
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement - TradingKey
Merck's cholesterol pill gets US FDA approval - Reuters
Merck cholesterol drug, Lipfendra, approved by FDA (MRK:NYSE) - Seeking Alpha
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia - Business Wire
Merck & Co., Inc. (MRK) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $MRK - MarketBeat
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga
Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled - TradingKey
Earnings Preview: What To Expect From Merck & Co.'s Report - Yahoo Finance
BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating - marketscreener.com
Why Merck Stock Is in the Spotlight Today - Benzinga
0.72%
0.59%
자본화:
|
볼륨(24시간):